Original Article
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
N Engl J Med 2006; 354:1231-1242March 23, 2006
- Abstract
Background
After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another.
Methods
We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology — Self Report (QIDS-SR-16), obtained at treatment visits, determined secondary outcomes, including remission (a score of 5 or less at exit) and response (a reduction of 50 percent or more on baseline scores).
Results
Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events.
Conclusions
After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression. (ClinicalTrials.gov number, NCT00021528.)
Media in This Article
Figure 1
Overview of Study Design.Figure 2
Weeks of Treatment until Remission, According to Drug.Article Activity
- Article
Major depressive disorder is associated with substantial morbidity, mortality, family burden, and health care costs.1 Since no single treatment is uniformly effective,2-4 subsequent interventions are often needed. Second-step treatments include augmenting the first agent with a second or discontinuing the first agent and beginning a second (switching). The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial used an equipoise, stratified, randomized design to evaluate the relative efficacy and tolerability of various antidepressant treatments for outpatients with nonpsychotic major depressive disorder who had a lack of remission or could not tolerate the selective serotonin-reuptake inhibitor (SSRI) citalopram (Celexa, Forest Pharmaceuticals) or subsequent treatments.2,4,5
The SSRIs are common first-step treatments, given their relatively low toxicity and high tolerability. Few randomized trials have compared the efficacy and tolerability of treatment with at least two active second agents after the initial failure of treatment with an SSRI.6-9 Open case series — typically in symptomatic volunteers with few psychiatric and general medical coexisting conditions10 — suggest variable response rates (25 to 65 percent) when the first SSRI is switched to a second SSRI,11-13 to a non-SSRI (an out-of-class switch),14-16 or to medications that inhibit the uptake of both serotonin and norepinephrine (“dual-action” agents).17-19
This report summarizes the overall study design for the first two treatment steps. In the current study, we compared outcomes achieved with three second-step medications: sustained-release bupropion (Wellbutrin SR, GlaxoSmithKline), sertraline (Zoloft, Pfizer), or extended-release venlafaxine (Effexor XR, Wyeth-Ayerst Laboratories).2,4 These medications are pharmacologically distinct. Sustained-release bupropion, an out-of-class agent, does not inhibit serotonin reuptake. Sertraline, a within-class switch, is an SSRI. Extended-release venlafaxine, a dual-action agent, inhibits the reuptake of both serotonin and norepinephrine.
Remission (as opposed to response) was chosen as the primary outcome. Remission, the virtual absence of depressive symptoms, was the goal of treatment3,20 and is associated with a better prognosis and day-to-day function than is response (i.e., a reduction in symptoms of at least 50 percent from baseline).21,22 Generally, in eight-week efficacy trials, remission rates are 35 to 40 percent, and response rates are 50 to 55 percent. Remission rates with citalopram as the first step in STAR*D were 28 to 33 percent, and response rates averaged 47 percent.23
Methods
Participants
Adult outpatients with a primary clinical diagnosis of nonpsychotic major depressive disorder,24 as confirmed by a checklist completed by the clinical research coordinators, were enrolled at primary and psychiatric public and private practice settings between July 2001 and August 2004. Broad inclusion and minimal exclusion criteria4 were used to maximize the generalizability of the findings.2,4
All study participants provided written informed consent at enrollment into the initial treatment with citalopram (level 1) and into all secondary treatments (level 2). All participants received citalopram as the initial treatment.23 Participants who were eligible for second-step treatments either had not had a remission or could not tolerate citalopram. A lack of remission was defined as a score of more than 5 on the 16-item Quick Inventory of Depressive Symptomatology — Clinician Rated (QIDS-C-16)25,26 at the last level 1 visit; scores can range from 0 to 27, with higher scores indicating greater severity of symptoms.
Figure 1Figure 1
Overview of Study Design. provides an overview of the study at levels 1 and 2. The study used an equipoise stratified, randomized design5 in which patients were strongly encouraged to accept all seven potential second-step treatments — the four switch options (including cognitive therapy) and three augmented treatments. However, to mimic practice, patients could opt to exclude certain level 2 treatment options. They could elect to exclude all switch options or all augmentation options, they could accept or decline cognitive therapy within either the switch or augmentation option, or they could accept only cognitive therapy (both as a switch and an augmentation treatment). In this design, the various acceptable treatments chosen by patients are called acceptability strata. Only the treatments for which patients accepted randomization were compared.5 By design, only the treatment groups that included a sufficient number of patients were analyzed to address the primary study aims. For level 2, the primary comparisons were among the three medication switches (sustained-release bupropion, sertraline, and extended-release venlafaxine), which are discussed in this report, and among the two medication augmentations (reported by Trivedi et al. elsewhere in this issue of the Journal 27). Randomization was conducted in a 1:1:1 ratio separately within each regional center and according to which treatments the participants accepted.
The institutional review boards at the national coordinating center, the data coordinating center, and regional centers and at relevant clinical sites and the data safety and monitoring board of the National Institute of Mental Health approved and monitored the protocol.
All authors were involved in study implementation, supervision, data review, and manuscript development. Bristol-Myers Squibb, Forest Pharmaceuticals, GlaxoSmithKline, King Pharmaceuticals, Organon, Pfizer, and Wyeth-Ayerst Laboratories provided medications at no cost for this trial but otherwise had no role in the design, conduct, data analysis, or drafting of the manuscript reporting the results.
Protocol Treatment
To mimic clinical practice, enhance safety, ensure a vigorous dosing regimen, and maximize generalizability, all participants and treating clinicians were aware of treatment assignments and doses. A clinical treatment manual (available at www.star-d.org) with an emphasis on measurement-based care23 recommended starting doses and dose changes on the basis of scores for the clinician-rated (QIDS-C-16) version of the 16-item Quick Inventory of Depressive Symptomatology (a scale ranging from 0 to 27, with higher scores indicating a greater severity of symptoms)25,26 and the Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) (a rating scale that collects information on the frequency, intensity, and burden of side effects, each on a 7-point scale with higher ratings indicating greater severity) obtained at each treatment.4 (A copy of the manual can be found in the Supplementary Appendix, available with the full text of this article at www.nejm.org.) In addition, didactic instruction, support by the clinical research coordinators, and a centralized monitoring system28 with feedback ensured timely increases in doses when an inadequate reduction in symptoms occurred in the context of acceptable side effects.23 Treatment was aimed at symptom remission, which was defined as a QIDS-C-16 score of 5 or less at the clinic visit.
At the initiation of the switch in medications, citalopram was discontinued without a tapering or washout period. The recommended daily dose of sustained-release bupropion was 150 mg for seven days, 200 mg from day 8 to 27, 300 mg from day 28 to 41, and 400 mg from day 42 onward. Sertraline was started at a daily dose of 50 mg and increased to 100 mg at day 14, to 150 mg at day 28, and to 200 mg at day 63. For extended-release venlafaxine, the starting daily dose of 37.5 mg for 7 days was increased to 75 mg from day 8 to 14, to 150 mg from day 15 to 27, to 225 mg from day 28 to 41, to 300 mg from day 42 to 62, and to 375 mg from day 63 onward. Dosing recommendations were flexible and were based on clinical judgment as informed by the FIBSER and the QIDS-C-16 scores at each treatment visit.
Concomitant Treatments
Stimulants, anticonvulsants, antipsychotic agents, mood stabilizers, nonprotocol antidepressant medications, and potential antidepressant augmenting agents (e.g., buspirone) were proscribed. Otherwise, any concomitant medication was allowed as necessary to manage concurrent general medical conditions or the side effects of protocol antidepressants (e.g., sexual dysfunction), as were anxiolytic agents (with the exception of alprazolam) and sedative hypnotic agents (including trazodone, at a dose of 200 mg or less at bedtime, for sleep).
Clinical Measurements
Information collected at level 1 baseline to describe the study cohort included scores for the Cumulative Illness Rating Scale (CIRS)29 to assess patients' general medical conditions, the Psychiatric Diagnostic Screening Questionnaire30,31 to identify coexisting psychiatric disorders, and the 30-item Inventory of Depressive Symptomatology — Clinician Rated26,32 (IDS-C30) to assess the severity of depression and certain symptom features.33 Assessments of overall function — including the Short-Form Health Survey (SF-12), Work Productivity and Activity Impairment Questionnaire, Work and Social Adjustment Scale (WSAS) — and satisfaction (Quality of Life Enjoyment and Satisfaction Questionnaire [QLESQ]) were collected by an automated interactive-voice-response telephone system.34
The primary outcome (i.e., symptom remission) was defined as a total score of 7 or less on the 17-item Hamilton Depression Rating Scale35 (HRSD-17), which was obtained in telephone-based, structured interviews (in either English or Spanish) conducted by independent research-outcome assessors who were unaware of treatment-group assignment within five days after entry and exit from the study. The secondary outcomes included results on the Quick Inventory of Depressive Symptomatology — Self-Report (QIDS-SR-16)2,4,25,26 and the FIBSER4 obtained at each treatment visit. QIDS-SR-16 remission was defined as a total score at study exit of 5 or less, and response was defined as a reduction of 50 percent or more (level 2 baseline to exit) on the QIDS-SR-16.
Statistical Analysis
Summary statistics are presented as means (±SD) for continuous variables and percentages for discrete variables. Parametric and nonparametric analysis-of-variance methods and chi-square tests were used to compare the baseline clinical and demographic characteristics, treatment features, and rates of side effects and serious adverse events among treatment groups.
All analyses were conducted according to the intention to treat.36 Logistic-regression models were used to determine whether there was an independent treatment effect on remission and response rates, adjusting for the effect of the regional center and acceptability stratum. Thirteen design variables were included in the logistic-regression models to estimate the effect of differences among the 14 regional centers. For this report, eight treatment-acceptability strata for medication switches were possible. These strata were collapsed into two strata (“medication switch only” and “other”) because of small numbers of patients in several strata. Thus, one design variable was included in the logistic models to control for the effect of the acceptability. Times to first remission (a score of 5 or less on the QIDS-SR-16) and first response (a reduction in the baseline score of 50 percent or more on the QIDS-SR-16) were defined as the first observed point with the use of data from clinic visits. Log-rank tests were used to compare the cumulative proportion with rates of remission and response among the three treatment groups. Exploratory logistic-regression analyses were used to determine whether there was a differential effect of treatment among patients who could not tolerate treatment in level 1.
At the end of this study, patients with missing HRSD-17 scores were assumed not to have had a remission (as originally defined).4 To determine whether this assumption affected study results, we conducted sensitivity analyses. The analyses were replicated with the use of two additional methods of imputation, a multiple imputation method37 and imputed values generated from item-response theory, which mapped total scores on the QIDS-SR-16 to corresponding values on the HRSD-17.38 Consistent findings indicated that the results were not affected by this approach to missing data.
Results
Patients
Figure 1 shows how the study groups in this trial (and the study by Trivedi et al.27) were developed on the basis of the various acceptability strata. Only 21 of 1439 patients (1.5 percent) accepted random assignment to any of the seven level 2 treatments. Furthermore, only 369 of 1439 patients (25.6 percent) included cognitive therapy among any of the acceptable treatments.
Of the 727 participants, 239 received sustained-release bupropion, 238 received sertraline, and 250 received extended-release venlafaxine. The majority of these participants were drawn from two groups who were defined by the treatments that they found acceptable (Figure 1), mainly from the 583 patients who accepted only the three medication switch treatments and the 104 patients who accepted only the four switch treatments (i.e., the three medication switches plus cognitive therapy alone).
Demographic and Clinical Characteristics
Participants had index episodes of depression with low function that were defined as recurrent (75.7 percent of the patients), early onset (37.2 percent), or chronic (27.0 percent) (Table 1Table 1
Clinical and Demographic Characteristics of Patients.). The characteristics of the patients were similar to those of the patients who entered level 1 and who could be evaluated.23 For example, the mean (±SD) scores for the HRSD-17 were 21.8±5.2 at entry into level 1 and 18.9±7.3 at entry into this study. Of the 727 enrollees, 407 patients could not tolerate citalopram (56.0 percent), as defined by the discontinuation of level 1 treatment before four weeks for any reason or after four weeks because of intolerable side effects. The results in the three medication groups were similar. The number of concurrent psychiatric disorders (data not shown) did not differ significantly among the three treatment groups.Treatment Features
Table 2Table 2
Characteristics of Treatment. shows the course of treatment with each medication. All three medications were administered in adequate doses for substantial periods, though only 32.8 percent of patients who received extended-release venlafaxine took more than 225 mg per day.Symptom Outcomes
Remission rates, on the basis of the results on the HRSD-17, did not differ significantly among treatment groups (χ2=3.649 with 2 df, P=0.16). Of 239 patients who received sustained-release bupropion, 51 had a remission (21.3 percent), as did 42 of 238 patients who received sertraline (17.6 percent) and 62 of 250 patients who received extended-release venlafaxine (24.8 percent). The treatments did not differ significantly with respect to the QIDS-SR-16 response rates, remission rates, or percent reductions in QIDS-SR-16 scores (Table 3Table 3
Treatment Outcomes, Side Effects, and Serious Adverse Events.).The treatments also did not differ significantly with respect to either time to remission (log rank χ2=0.38, P=0.93) (Figure 2Figure 2
Weeks of Treatment until Remission, According to Drug.) or time to response (log rank χ2=0.65, P=0.72) on the basis of results on the QIDS-SR-16. Among the patients who had a remission, the mean time to remission according to results on the QIDS-SR-16 was 5.4±4.5 weeks (median, 4.0) for those given sustained-release bupropion, 6.2±5.0 weeks (median, 4.9) for those given sertraline, and 5.5±4.7 weeks (median, 4.2) for those given extended-release venlafaxine. Similarly, among patients with a response, according to results on the QIDS-SR-16, the mean time to a response was 5.5±3.5 weeks (median, 4.0) for those given sustained-release bupropion, 6.6±4.3 weeks (median, 5.9) for those given sertraline, and 7.0±4.3 weeks (median, 6.0) for those given extended-release venlafaxine.Tolerability and Adverse Events
Side effects and serious adverse events were clinically similar among the treatment groups (Table 3). The treatments did not differ significantly in the overall burden of side effects or in the proportion of patients with any serious psychiatric adverse event, though there was a difference in the distribution of the frequency of side effects. Four patients were hospitalized for suicidal ideation or attempted suicide, but none committed suicide during the trial.
Discussion
In the context of the equipoise stratified, randomized design used in this trial, which gave patients choices in their treatment regimen, most patients opted to have their medication either switched or augmented. Few patients chose to do both, thus preventing a definitive comparison of strategies involving augmentation with those involving a switch medication. Our results suggest that such a choice (i.e., both augmentation and a switch medication) is relatively uncommon in practice when patients are provided options.
With regard to the commonly accepted practice of switching medications, approximately one in four depressed patients had a remission of symptoms with sustained-release bupropion, sertraline, or extended-release venlafaxine after either not having had a remission with or being unable to tolerate citalopram therapy. Remission rates did not differ significantly among the three medication groups nor did QIDS-SR-16 response rates, times to QIDS-SR-16 response, change in QIDS-SR-16 scores from baseline to the end of the study, serious adverse events, or measures of tolerability. Remission rates were slightly higher according to results on the QIDS-SR-16 than to results on the HRSD-17, because patients who did not undergo HRSD-17 evaluation at the end of the study were declared a priori not to have had a remission. Of the 209 patients with missing HRSD-17 scores, 26 had a remission (12.4 percent) on the basis of results on the QIDS-SR-16. On the basis of results on the HRSD-17, no differential treatment effect in regard to remission was found between patients who could not tolerate citalopram and those who could tolerate this agent. These findings are generalizable to most adult outpatients with a nonpsychotic major depressive disorder who are treated in primary or specialty care settings.
Rates of response and remission with each switch medication were lower than rates reported in open-label case series of switch medications after failure of treatment with an SSRI. Such series typically involved patients who were not chronically depressed, had few coexisting medical or psychiatric illnesses, and were treated in research clinics.10 On the basis of results on the HRSD-17, remission rates were also slightly lower than the overall rate of 30 percent with medication augmentation as the second treatment step (as described by Trivedi et al.27). However, these two trial groups of the STAR*D study involved largely distinct groups of patients who had different outcomes with citalopram treatment. Patients in our study had greater rates of intolerance to and somewhat less benefit from citalopram. Although the remission rates in our trial are clinically meaningful, the relatively low rates were probably not due to inadequate doses of medication or to inadequate durations of treatment, given the mean doses at the end of treatment and durations of treatment for each agent. However, the dose of extended-release venlafaxine was less likely to approach the protocol-recommended maximum of 375 mg per day than was the dose of either of the other two drugs.
These findings have important practical implications. Contrary to the belief that intolerance of one SSRI predicts intolerance of another SSRI, sertraline was tolerated as well as sustained-release bupropion, even though 56.0 percent of patients in this trial could not tolerate citalopram. Thus, intolerance to or the lack of efficacy of one SSRI seems not to imply intolerance or lack of efficacy of another SSRI. These results indicate that both within-class and out-of-class medication switches are reasonable choices.
As for the dual-action agent extended-release venlafaxine, post hoc pooled analyses39,40 have suggested slightly higher remission rates with venlafaxine than with SSRIs when used as first-step treatment. No studies, to our knowledge, have compared venlafaxine with other potentially active medications at the second treatment step. In this study, higher remission rates were not achieved with extended-release venlafaxine than with the more selective agents among patients who could not tolerate or who did not have a remission with citalopram therapy.
Important limitations to this comparison of three switch medications include the lack of placebo control and unblinded delivery of treatment, though assessment of the primary outcome (according to results on the HRSD-17) was done in a blinded fashion, and the QIDS-SR-16 and HRSD-17 ratings were in agreement. A placebo-controlled study is not needed to discern whether these three switch treatments differ, but without a placebo group, we cannot be certain that any of the treatments was specifically effective (i.e., the results were due to the pharmacologic effects of the medication). On the other hand, switching to a placebo after an initial failed treatment would have aroused concern about ethics,41 might have limited generalizability (if more severely or chronically ill patients had declined to enroll), or might have led to less vigorous administration of drugs, given the high prevalence of coexisting medical conditions among the patients. In addition, since few patients opted for both augmentation of their medication and switching to another drug, we cannot definitively compare these two strategies. Finally, we cannot determine the basis for the choices exercised by patients, since we did not ask them why they had made such choices.
Among patients who cannot tolerate or who do not have a remission in response to an initial SSRI, approximately one in four patients had a remission on switching to sustained-release bupropion, sertraline, or extended-release venlafaxine; these three drugs had similar efficacy and tolerability. These findings highlight the need for more broadly effective antidepressant treatments.
Supported by a contract (N01MH90003, to the University of Texas Southwestern Medical Center at Dallas) with the National Institute of Mental Health with National Institutes of Health. Bristol-Myers Squibb, Forest Pharmaceuticals, GlaxoSmithKline, King Pharmaceuticals, Organon, Pfizer, and Wyeth-Ayerst Laboratories provided medications at no cost for this trial.
The content of this article does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement.
Dr. Rush reports having received consulting fees from or having served on advisory boards for Advanced Neuronetic Systems, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, HealthCare Technology Systems, Merck, Neuronetics, Organon, Ono Pharmaceuticals, and Wyeth-Ayerst Laboratories; royalties from Guilford Press and Health Technology Systems; and lecture fees from Cyberonics, Forest Pharmaceuticals, GlaxoSmithKline, and Merck; and having an equity interest in Pfizer. Dr. Trivedi reports having received consulting fees from or having served on advisory boards for Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Pharmaceuticals, Johnson & Johnson, Pfizer, Sepracor, and Wyeth-Ayerst Laboratories; speaker fees from Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Pharmaceuticals, and Wyeth-Ayerst Laboratories; and research support from Bristol-Myers Squibb, Cephalon, Corcept Therapeutics, Eli Lilly, Janssen Pharmaceutica, Pfizer, Predix Pharmaceuticals, and Wyeth-Ayerst Laboratories. Dr. Stewart reports having received lecture or consulting fees or research support from Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Organon, Shire, and Somerset. Dr. Nierenberg reports having received consulting fees from Eli Lilly, Genaissance, GlaxoSmithKline, Innapharma, Sepracor, and Shire; research support from Bristol-Myers Squibb, Cederroth, Cyberonics, Forest Pharmaceuticals, Janssen Pharmaceutica, Lichtwer Pharma, and Pfizer; and both research support and honorariums from Eli Lilly, GlaxoSmithKline, and Wyeth-Ayerst Laboratories. Dr. Thase reports having received consulting fees from AstraZeneca, Bristol-Myers Squibb, Cephalon, Cyberonics, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica, Novartis, Organon, Pfizer, and Wyeth-Ayerst Laboratories; and lecture fees from AstraZeneca, Eli Lilly, GlaxoSmithKline, Organon, and Wyeth-Ayerst Laboratories. Dr. Biggs reports having received consulting fees from Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, and Pfizer. Dr. Warden reports having had equity interests in Pfizer and Bristol-Myers Squibb. Dr. Fava reports having received research support from Abbott Laboratories, Lichtwer Pharma, and Lorex Pharmaceuticals; lecture fees from Bayer AG, Biovail, BrainCells, Compellis, Cypress Pharmaceutical, Dov Pharmaceutical, Grunenthal, Janssen Pharmaceutica, Knoll Pharmaceutical, Lundbeck, Pamlab, Sepracor, and Somerset Pharmaceuticals; and research support and honorariums from Aspect Medical Systems, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson, Novartis, Organon, Pharmavite, Pfizer, Roche, Sanofi-Synthelabo, Solvay Pharmaceuticals, and Wyeth-Ayerst Laboratories. No other potential conflict of interest relevant to this article was reported.
This study is dedicated to the memory of Fred Quitkin, M.D., our dear friend and colleague.
Source Information
From the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas (A.J.R., M.H.T., M.M.B., D.W., K.S.-W.); the Epidemiology Data Center, Graduate School of Public Health, University of Pittsburgh (S.R.W., J.F.L.), and the Department of Psychiatry, University of Pittsburgh School of Medicine (M.E.T.) — both in Pittsburgh; the New York State Psychiatric Institute and Columbia College of Physicians and Surgeons, New York (J.W.S.); the Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston (A.A.N., M.F.); and the National Institute of Mental Health, Bethesda, Md. (L.R., G.N.).
Address reprint requests to Dr. Rush at the Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75390-9086, or at john.rush@utsouthwestern.edu.
The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial investigators are listed in the Appendix.
Appendix
The following investigators participated in the STAR*D trial: National Coordinating Center — A.J. Rush, M. Trivedi, D. Warden, M.M. Biggs, K. Shores-Wilson, D. Stegman, M. Kashner; Data Coordinating Center — S. Wisniewski, G.K. Balasubramani, J. Luther, H. Eng; Regional Centers: University of Alabama, Birmingham, and Tuscaloosa Veterans Affairs Medical Center, Tuscaloosa, Ala. — L. Davis, K. Rice, A. Berry, P. Johnson, S. Ambrose, M. Jewell, B. Thomas, E. Waldrop, T. Allen, E. St. John, R. Williams; University of California, Los Angeles — A. Leuchter, I. Lesser, I. Cook, M. Epstein, S. Rosenberg, S. Zeim, L. Sulkowski, J. Iribarren, R. Armstrong, A. Rosales, M. Abrams; University of California, San Diego — S. Zisook, K. Harless, C. Gonzalez, M. Smith, C. Lawrence, J. Palica, M. Rohrs, M. Capous-Desyllas, K. Ganadjian; Northwestern University Medical School, Chicago — W. McKinney, W. Gilmer, C. Kelley, C. Cooler, A. Bauer, J. Fleck, C. Endick: Psychiatric Research Institute, University of Kansas, Wichita — S. Preskorn, D. Hilger, A. Klick-Davis, R. Lusk, J. Elmore, D. Soetaert; Massachusetts General Hospital, Boston — J. Alpert, M. Fava, A. Nierenberg, A. Farabaugh, T. Petersen, W. Merens, P. Cassano, N. Craven, H. Yang, M. Candrian, R. Fraguas; University of Michigan, Ann Arbor — E. Young, S. Marcus, J. Greden, H. Briggs, K. Bullard, A. Kennedy, A. Benway, E. Rickard; New York State Psychiatric Institute and Columbia College of Physicians and Surgeons, New York — F.M. Quitkin, P. McGrath, J.W. Stewart, H. Sackeim, K. Tate-Brown, S. Rees, C. Smith, A. Couraud, J. Lavelle, K. Broderick; University of North Carolina, Chapel Hill — R. Golden, B. Gaynes, J. DeVeaugh-Geiss, A. Ford, S. Barnett, B. Pearson; Laureate Healthcare System, Tulsa, Okla. — J. Mitchell, W. Yates, J. Kuehnert, L. Jernigan, B. Williams, J. Hilton; University of Pittsburgh Medical Center, Pittsburgh — M. Thase, R.H. Howland, E. Friedman, J. Callan, S. Berman, L. Shutt, C. Spotts; Vanderbilt University Medical Center, Nashville — S. Hollon, R. Shelton, M. Lovett, T. Crutcher, T. Patton, J. Hart, R.M. Harris-Turner, D. Lilly, B. Sirles, S. Hicks, N. Harris, S. Addington; University of Texas Southwestern Medical Center, Dallas — M. Husain, M. Downing, D. Stegman, E. Shellhorn, B. O'Neal, D. Turner, L. MacLeod, M. Henson, T. Hawley, S. Gardner; Virginia Commonwealth University, Richmond — S. Kornstein, R. Schneider, S. Belyea, B. Perry, K. Schmitt, T. Goff, K. Lamoree, M. Britton, C. Glassman.
- References
References
1
Agency for Health Care Policy and Research. Depression in primary care. Vol. 1. Detection and diagnosis. Rockville, Md.: Department of Health and Human Services, 1993. (AHCPR publication no. 93-0550.)
2
Fava M ,Rush AJ ,Trivedi MH , et al. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatr Clin North Am 2003;26:457-494
CrossRef | Web of Science | Medline3
Agency for Health Care Policy and Research. Depression in primary care. Vol. 2. Treatment of major depression. Rockville, Md.: Department of Health and Human Services, 1993. (AHCPR publication no. 93-0551.)
4
Rush AJ ,Fava M ,Wisniewski SR , et al. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Control Clin Trials 2004;25:119-142
CrossRef | Medline5
Lavori PW ,Rush AJ ,Wisniewski SR , et al. Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry 2001;50:792-801
CrossRef | Web of Science | Medline6
Poirier MF ,Boyer P . Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. Br J Psychiatry 1999;175:12-16[Erratum, Br J Psychiatry 1999;175:394.]
CrossRef | Web of Science | Medline7
Nolen WA ,van de Putte JJ ,Dijken WA , et al. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand 1988;78:676-683
CrossRef | Web of Science | Medline8
Nolen WA ,van de Putte JJ ,Dijken WA , et al. Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand 1988;78:668-675
CrossRef | Web of Science | Medline9
Nolen WA ,Haffmans PM ,Bouvy PF ,Duivenvoorden HJ . Monoamine oxidase inhibitors in resistant major depression: a double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. J Affect Disord 1993;28:189-197
CrossRef | Web of Science | Medline10
Fava M . Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry 2000;61:Suppl 2:10-12
Web of Science | Medline11
Joffe RT ,Levitt AJ ,Sokolov ST ,Young LT . Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996;57:114-115
Web of Science | Medline12
Thase ME ,Blomgren SL ,Birkett MA ,Apter JT ,Tepner RG . Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997;58:16-21
CrossRef | Web of Science | Medline13
Thase ME ,Feighner JP ,Lydiard RB . Citalopram treatment of fluoxetine nonresponders. J Clin Psychiatry 2001;62:683-687
CrossRef | Web of Science | Medline14
Fava M ,Dunner DL ,Greist JH , et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry 2001;62:413-420
CrossRef | Web of Science | Medline15
Fava M ,McGrath PJ ,Sheu WP . Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. J Clin Psychopharmacol 2003;23:365-369
CrossRef | Web of Science | Medline16
Fava M ,Papakostas GI ,Petersen T , et al. Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatry 2003;15:17-22
Medline17
de Montigny C ,Silverstone PH ,Debonnel G ,Blier P ,Bakish D . Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol 1999;19:401-406
CrossRef | Web of Science | Medline18
Nierenberg AA ,Feighner JP ,Rudolph R ,Cole JO ,Sullivan J . Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-423
CrossRef | Web of Science | Medline19
Saiz-Ruiz J ,Ibanez A ,Diaz-Marsa M , et al. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1129-1134
CrossRef | Web of Science | Medline20
American Psychiatric Association
Web of Science21
Judd LL ,Paulus MP ,Zeller P . The role of residual subthreshold depressive symptoms in early episode relapse in unipolar major depressive disorder. Arch Gen Psychiatry 1999;56:764-765
CrossRef | Web of Science | Medline22
Miller IW ,Keitner GI ,Schatzberg AF , et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998;59:608-619
CrossRef | Web of Science | Medline23
Trivedi MH ,Rush AJ ,Wisniewski SR , et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
CrossRef | Web of Science | Medline24
Diagnostic and statistical manual of mental disorders, 4th ed.: DSM-IV. Washington, D.C.: American Psychiatric Association, 1994.
25
Rush AJ ,Trivedi MH ,Ibrahim HM , et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54:573-583[Erratum, Biol Psychiatry 2003;54:585.]
CrossRef | Web of Science | Medline26
Trivedi MH ,Rush AJ ,Ibrahim HM , et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004;34:73-82
CrossRef | Web of Science | Medline27
Trivedi MH ,Fava M ,Wisniewski SR , et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-1252
Full Text | Web of Science | Medline28
Wisniewski SR ,Eng H ,Meloro L , et al. Web-based communications and management of a multi-center clinical trial: the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project. Clin Trials 2004;1:387-398
CrossRef | Medline29
Linn BS ,Linn MW ,Gurel L . Cumulative illness rating scale. J Am Geriatr Soc 1968;16:622-626
Web of Science | Medline30
Zimmerman M ,Mattia JI . A self-report scale to help make psychiatric diagnoses: the Psychiatric Diagnostic Screening Questionnaire. Arch Gen Psychiatry 2001;58:787-794
CrossRef | Web of Science | Medline31
Rush AJ ,Zimmerman M ,Wisniewski SR , et al. Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J Affect Disord 2005;87:43-55
CrossRef | Web of Science | Medline32
Rush AJ ,Gullion CM ,Basco MR ,Jarrett RB ,Trivedi MH . The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996;26:477-486
CrossRef | Web of Science | Medline33
Novick JS ,Stewart JW ,Wisniewski SR , et al. Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. J Clin Psychiatry 2005;66:1002-1011
CrossRef | Web of Science | Medline34
Trivedi MH ,Rush AJ ,Wisniewski SR , et al. Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry 2006;67:185-195
CrossRef | Web of Science | Medline35
Hamilton M . A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
CrossRef | Web of Science | Medline36
Fisher L, Dixon D, Herson J, Frankowski R, Hearron M, Peace K. Intention-to-treat in clinical trials. In: Peace KE, ed. Statistical issues in drug research and development. New York: Marcel Dekker, 1990.
37
Schafer JL . Multiple imputation: a primer. Stat Methods Med Res 1999;8:3-15
CrossRef | Web of Science | Medline38
Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: a STAR*D report. Biol Psychiatry (in press).
39
Thase ME ,Entsuah AR ,Rudolph RL . Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241
CrossRef | Web of Science | Medline40
Smith D ,Dempster C ,Glanville J ,Freemantle N ,Anderson I . Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404
CrossRef | Web of Science | Medline41
Rush AJ ,Thase ME ,Dube S . Research issues in the study of difficult-to-treat depression. Biol Psychiatry 2003;53:743-753
CrossRef | Web of Science | Medline
- Citing Articles (205)
Citing Articles
1
James E. Aikens, Michael S. Klinkman. (2012) Changes in patients' beliefs about their antidepressant during the acute phase of depression treatment. General Hospital Psychiatry
CrossRef2
J. F. Scherrer, T. Chrusciel, L. D. Garfield, K. E. Freedland, R. M. Carney, P. J. Hauptman, K. K. Bucholz, R. Owen, P. J. Lustman. (2012) Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction. The British Journal of Psychiatry
CrossRef3
F. Martínez-Granados, E. Climent-Grana, E. Pérez-Martínez, J.P. Ordovás-Baines, J. Selva Otaolaurruchi, M.A. Bernabéu Martínez. (2012) Assessing a Therapeutic Exchange Protocol for Second-generation Antidepressants: Clinical Results. Farmacia Hospitalaria (English Edition)
CrossRef4
&NA;. (2011) Consider augmentation or switching strategies when first-line antidepressants are unsuccessful in major depressive disorder. Drugs & Therapy Perspectives 27:12, 7-12
CrossRef5
Shinichiro Nakajima, Hiroyuki Uchida, Takefumi Suzuki, Koichiro Watanabe, Jinichi Hirano, Tatsuhiko Yagihashi, Hiroyoshi Takeuchi, Takayuki Abe, Haruo Kashima, Masaru Mimura. (2011) Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: A randomized open-label trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35:8, 1983-1989
CrossRef6
Michele Fornaro, Eugenio Aguglia, Liliana Dell'Osso, Giulio Perugi. (2011) Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?. Expert Opinion on Pharmacotherapy 12:18, 2817-2831
CrossRef7
David L. Mintz, David F. Flynn. (2011) How (Not What) to Prescribe: Nonpharmacologic Aspects of Psychopharmacology. Psychiatric Clinics of North America
CrossRef8
Sophie Mouillet-Richard, Anne Baudry, Jean-Marie Launay, Odile Kellermann. (2011) MicroRNAs and depression. Neurobiology of Disease
CrossRef9
Richard A. Hansen, Stacie B. Dusetzina, Alan R. Ellis, Til Stürmer, Joel F. Farley, Bradley N. Gaynes. (2011) Risk of adverse events in treatment-resistant depression: propensity-score-matched comparison of antidepressant augment and switch strategies. General Hospital Psychiatry
CrossRef10
Roland Ricken, Katja Wiethoff, Thomas Reinhold, Kathrin Schietsch, Thomas Stamm, Julia Kiermeir, Peter Neu, Andreas Heinz, Michael Bauer, Mazda Adli. (2011) Algorithm-guided treatment of depression reduces treatment costs — Results from the randomized controlled German Algorithm Project (GAPII). Journal of Affective Disorders 134:1-3, 249-256
CrossRef11
, Thomas C. Baghai, Pierre Blier, David S. Baldwin, Michael Bauer, Guy M. Goodwin, Kostas N. Fountoulakis, Siegfried Kasper, Brian E. Leonard, Ulrik F. Malt, Dan Stein, Marcio Versiani, Hans-Jürgen Möller. (2011) General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. European Archives of Psychiatry and Clinical Neuroscience 261:S3, 207-245
CrossRef12
Bradley N. Gaynes, Joel F. Farley, Stacie B. Dusetzina, Alan R. Ellis, Richard A. Hansen, William C. Miller, Til Stürmer. (2011) Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?. Depression and Anxiety 28:11, 989-998
CrossRef13
Jamie M. Dupuy, Michael J. Ostacher, Jeffrey Huffman, Roy H. Perlis, Andrew A. Nierenberg. (2011) A critical review of pharmacotherapy for major depressive disorder. The International Journal of Neuropsychopharmacology 14:10, 1417-1431
CrossRef14
Shawn M. McClintock, Mustafa M. Husain, Ira H. Bernstein, Stephen R. Wisniewski, Madhukar H. Trivedi, David Morris, Jonathan Alpert, Diane Warden, James F. Luther, Susan G. Kornstein, Melanie M. Biggs, Maurizio Fava, A. John Rush. (2011) Assessing anxious features in depressed outpatients. International Journal of Methods in Psychiatric Researchn/a-n/a
CrossRef15
Laura J. Thomas, Anna Abel, Nicola Ridgway, Tim Peters, David Kessler, Sandra Hollinghurst, Katrina Turner, Anne Garland, Bill Jerrom, Jill Morrison, Chris Williams, John Campbell, Willem Kuyken, Glyn Lewis, Nicola Wiles. (2011) Cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment resistant depression in primary care: The CoBalT randomised controlled trial protocol. Contemporary Clinical Trials
CrossRef16
Ricardo Moreira. (2011) The Efficacy and Tolerability of Bupropion in the Treatment of Major Depressive Disorder. Clinical Drug Investigation 31, 5-17
CrossRef17
Xianchen Liu, Zhanglin Cui, Liyuan Niu, Douglas E. Faries, Tamara Ball, Bryan Johnstone. (2011) Dosing Patterns for Duloxetine and Predictors of High-Dose Prescriptions in Patients with Major Depressive Disorder: Analysis from a United States Third-Party Payer Perspective. Clinical Therapeutics
CrossRef18
Charlotte L. Allan, Klaus P. Ebmeier. (2011) The Use of ECT and MST in treating depression. International Review of Psychiatry 23:5, 400-412
CrossRef19
F. Martínez-Granados, E. Climent-Grana, E. Pérez-Martínez, J.P. Ordovás-Baines, J. Selva Otaolaurruchi, M.A. Bernabéu Martínez. (2011) Evaluación de un protocolo de intercambio terapéutico de antidepresivos de segunda generación: resultados clínicos. Farmacia Hospitalaria 35:5, 244-253
CrossRef20
C.J. Guico-Pabia, Q. Jiang, P.T. Ninan, M.E. Thase. (2011) Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders. Current Medical Research and Opinion 27:9, 1815-1826
CrossRef21
Paolo Olgiati, Emanuele Bajo, Marco Bigelli, Diana De Ronchi, Alessandro Serretti. (2011) Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. Progress in Neuro-Psychopharmacology and Biological Psychiatry
CrossRef22
Daniel Souery, Alessandro Serretti, Raffaella Calati, Pierre Oswald, Isabelle Massat, Anastasios Konstantinidis, Sylvie Linotte, Siegfried Kasper, Stuart Montgomery, Joseph Zohar, Julien Mendlewicz. (2011) Citalopram versus desipramine in treatment resistant depression: Effect of continuation or switching strategies. A randomized open study. World Journal of Biological Psychiatry 12:5, 364-375
CrossRef23
Sidney H. Kennedy. (2011) Improving the clinical effectiveness of antidepressant treatment. Journal of Affective Disorders 132, S1-S2
CrossRef24
Jolanda Prins, Berend Olivier, S Mechiel Korte. (2011) Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited. Expert Opinion on Investigational Drugs 20:8, 1107-1130
CrossRef25
Daniel Souery, Alessandro Serretti, Raffaella Calati, Pierre Oswald, Isabelle Massat, Anastasios Konstantinidis, Sylvie Linotte, Joseph Bollen, Koen Demyttenaere, Siegfried Kasper, Yves Lecrubier, Stuart Montgomery, Joseph Zohar, Julien Mendlewicz. (2011) Switching Antidepressant Class Does Not Improve Response or Remission in Treatment-Resistant Depression. Journal of Clinical Psychopharmacology 31:4, 512-516
CrossRef26
G. Rosso, S. Rigardetto, F. Bogetto, G. Maina. (2011) A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression. Journal of Affective Disorders
CrossRef27
Daniel M. Blumberger, Benoit H. Mulsant, Paul B. Fitzgerald, Tarek K. Rajji, Arun V. Ravindran, L. Trevor Young, Andrea J. Levinson, Zafiris J. Daskalakis. (2011) A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression. World Journal of Biological Psychiatry1-13
CrossRef28
Erin K. Kastenschmidt, Gary J. Kennedy. (2011) Depression and Anxiety in Late Life: Diagnostic Insights and Therapeutic Options. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78:4, 527-545
CrossRef29
Michele Fabrazzo, Francesco Perris, Palmiero Monteleone, Giuseppina Esposito, Francesco Catapano, Mario Maj. (2011) Aripiprazole augmentation strategy in clomipramine-resistant depressive patients: An open preliminary study. European Neuropsychopharmacology
CrossRef30
Sonja Horstmann, Elisabeth B. Binder. (2011) Glucocorticoids as Predictors of Treatment Response in Depression. Harvard Review of Psychiatry 19:3, 125-143
CrossRef31
D. Gourion, A. Galinowski, L. Baraille, H. Picard. (2011) Changer d’antidépresseur : quand, comment, pourquoi ?. L'Encéphale 37, S50-S57
CrossRef32
F. Andrew Kozel, Kevin A. Johnson, Ziad Nahas, Paul A. Nakonezny, Paul S. Morgan, Berry S. Anderson, Samet Kose, Xingbao Li, Kelvin O. Lim, Madhukar H. Trivedi, Mark S. George. (2011) Fractional Anisotropy Changes After Several Weeks of Daily Left High-Frequency Repetitive Transcranial Magnetic Stimulation of the Prefrontal Cortex to Treat Major Depression. The Journal of ECT 27:1, 5-10
CrossRef33
Claudio N. Soares, Michael E. Thase, Anita Clayton, Christine J. Guico-Pabia, Kristen Focht, Qin Jiang, Susan G. Kornstein, Phillip T. Ninan, Cecelia P. Kane. (2011) Open-Label Treatment with Desvenlafaxine in Postmenopausal Women with Major Depressive Disorder Not Responding to Acute Treatment with Desvenlafaxine or Escitalopram. CNS Drugs 25:3, 227-238
CrossRef34
Gregory V. Carr, Irwin Lucki. (2011) The role of serotonin receptor subtypes in treating depression: a review of animal studies. Psychopharmacology 213:2-3, 265-287
CrossRef35
Paul R Albert, Brice Le François, Anne M Millar. (2011) Transcriptional dysregulation of 5-HT1A autoreceptors in mental illness. Molecular Brain 4:1, 21
CrossRef36
Paul E. Holtzheimer, Helen S. Mayberg. (2011) Stuck in a rut: rethinking depression and its treatment. Trends in Neurosciences 34:1, 1-9
CrossRef37
K. Ryan Connolly, Michael E. Thase. (2011) If at First You Donʼt Succeed. Drugs 71:1, 43-64
CrossRef38
Shulin Chen, Yeates Conwell, Baihua Xu, Helen Chiu, Xin Tu, Yan Ma. (2011) Depression care management for late-life depression in China primary care: Protocol for a randomized controlled trial. Trials 12:1, 121
CrossRef39
H. Edmund Pigott, Gregory S. Alter. (2011) In Response to ‘Do Pharmacotherapy and/or Psychotherapy Work in Depression? It Depends!’ and ‘Widespread Methodological Problems Limit Validity of Meta-Analytic Results’. Psychotherapy and Psychosomatics 80:4, 247-248
CrossRef40
P. Blomstedt, R. L. Sjöberg, M. Hansson, O. Bodlund, M. I. Hariz. (2011) Deep brain stimulation in the treatment of depression. Acta Psychiatrica Scandinavica 123:1, 4-11
CrossRef41
Pierre Blier, Claude Blondeau. (2011) Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder. Journal of Affective Disorders 128, S3-S10
CrossRef42
Toshi A Furukawa, Tatsuo Akechi, Shinji Shimodera, Mitsuhiko Yamada, Kazuhira Miki, Norio Watanabe, Masatoshi Inagaki, Naohiro Yonemoto. (2011) Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol. Trials 12:1, 116
CrossRef43
Stania A. Dejesus, Vanessa A. Diaz, Wanda C. Gonsalves, Peter J. Carek. (2011) Identification and Treatment of Depression in Minority Populations. The International Journal of Psychiatry in Medicine 42:1, 69
CrossRef44
Stania A. Dejesus, Vanessa A. Diaz, Wanda C. Gonsalves, Peter J. Carek. (2011) Identification and Treatment of Depression in Minority Populations. The International Journal of Psychiatry in Medicine 42:1, 69-83
CrossRef45
Andrew F. Leuchter, Ian A. Cook, Steven P. Hamilton, Katherine L. Narr, Arthur Toga, Aimee M. Hunter, Kym Faull, Julian Whitelegge, Anne M. Andrews, Joseph Loo, Baldwin Way, Stanley F. Nelson, Steven Horvath, Barry D. Lebowitz. (2010) Biomarkers to Predict Antidepressant Response. Current Psychiatry Reports 12:6, 553-562
CrossRef46
CHAD D. RETHORST, DANIEL M. LANDERS, CRAIG T. NAGOSHI, JULIANNA T. D. ROSS. (2010) Efficacy of Exercise in Reducing Depressive Symptoms across 5-HTTLPR Genotypes. Medicine & Science in Sports & Exercise 42:11, 2141-2147
CrossRef47
Jeff C. Huffman, Jonathan E. Alpert. (2010) An Approach to the Psychopharmacologic Care of Patients: Antidepressants, Antipsychotics, Anxiolytics, Mood Stabilizers, and Natural Remedies. Medical Clinics of North America 94:6, 1141-1160
CrossRef48
Yuji Kitaichi, Takeshi Inoue, Shin Nakagawa, Shuken Boku, Aya Kakuta, Takeshi Izumi, Tsukasa Koyama. (2010) Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. European Journal of Pharmacology 647:1-3, 90-96
CrossRef49
Dominique Milea, Florent Guelfucci, Nawal Bent-Ennakhil, Mondher Toumi, Jean-Paul Auray. (2010) Antidepressant monotherapy: A claims database analysis of treatment changes and treatment duration. Clinical Therapeutics 32:12, 2057-2072
CrossRef50
John M. Kelley, Ted J. Kaptchuk. (2010) Group analysis versus individual response: The inferential limits of randomized controlled trials. Contemporary Clinical Trials 31:5, 423-428
CrossRef51
2010. References. , 335-393.
CrossRef52
2010. References. , 165-193.
CrossRef53
Christian Dolder, Michael Nelson, Andrea Stump. (2010) Pharmacological and Clinical Profile of Newer Antidepressants. Drugs & Aging 27:8, 625-640
CrossRef54
Yiru Fang, Chengmei Yuan, Yifeng Xu, Jun Chen, Zhiguo Wu, Lan Cao, Zhenghui Yi, Wu Hong, Yong Wang, Kaida Jiang, Keming Gao, Xingjia Cui, Andrew A. Nierenberg. (2010) Comparisons of the Efficacy and Tolerability of Extended-Release Venlafaxine, Mirtazapine, and Paroxetine in Treatment-Resistant Depression. Journal of Clinical Psychopharmacology 30:4, 357-364
CrossRef55
Martin Bares, Martin Brunovsky, Tomas Novak, Miloslav Kopecek, Pavla Stopkova, Peter Sos, Vladimir Krajca, Cyril Höschl. (2010) The change of prefrontal QEEG theta cordance as a predictor of response to bupropion treatment in patients who had failed to respond to previous antidepressant treatments. European Neuropsychopharmacology 20:7, 459-466
CrossRef56
Raymond W. Lam, Sara Larsson Lönn, Nicolas Despiégel. (2010) Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis. International Clinical Psychopharmacology 25:4, 199-203
CrossRef57
Sidney H. Kennedy, Sakina J. Rizvi. (2010) Agomelatine in the Treatment of Major Depressive Disorder. CNS Drugs 24:6, 479-499
CrossRef58
Verinder Sharma, Mustaq Khan. (2010) Identification of bipolar disorder in women with postpartum depression. Bipolar Disorders 12:3, 335-340
CrossRef59
Timothy M. Piser. (2010) Linking the cytokine and neurocircuitry hypotheses of depression: A translational framework for discovery and development of novel anti-depressants. Brain, Behavior, and Immunity 24:4, 515-524
CrossRef60
William V Bobo, Richard C Shelton. (2010) Efficacy, safety and tolerability of Symbyax ® for acute-phase management of treatment-resistant depression. Expert Review of Neurotherapeutics 10:5, 651-670
CrossRef61
J. Spijker, W. A. Nolen. (2010) An algorithm for the pharmacological treatment of depression. Acta Psychiatrica Scandinavica 121:3, 180-189
CrossRef62
Ciara McCabe, Zevic Mishor, Philip J. Cowen, Catherine J. Harmer. (2010) Diminished Neural Processing of Aversive and Rewarding Stimuli During Selective Serotonin Reuptake Inhibitor Treatment. Biological Psychiatry 67:5, 439-445
CrossRef63
T. Bschor, C. Baethge. (2010) No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatrica Scandinavica 121:3, 174-179
CrossRef64
Gahan J. Pandina, Georges M. Garibaldi, Dennis A. Revicki, Leah Kleinman, Ibrahim Turkoz, Mary J. Kujawa, Ramy A. Mahmoud. (2010) Psychometric evaluation of a Patient-Rated Most Troubling Symptom Scale for Depression: findings from a secondary analysis of a clinical trial. International Clinical Psychopharmacology 25:2, 51-59
CrossRef65
Hans-Jürgen Möller, Wolfgang Maier. (2010) Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. European Archives of Psychiatry and Clinical Neuroscience 260:1, 25-39
CrossRef66
A. F. Leuchter, M. M. Husain, I. A. Cook, M. H. Trivedi, S. R. Wisniewski, W. S. Gilmer, J. F. Luther, M. Fava, A. J. Rush. (2010) Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. Psychological Medicine 40:02, 239
CrossRef67
Richard C. Shelton, Olawale Osuntokun, Alexandra N. Heinloth, Sara A. Corya. (2010) Therapeutic Options for Treatment-Resistant Depression. CNS Drugs 24:2, 131-161
CrossRef68
Tom Bschor. (2010) Therapy-resistant depression. Expert Review of Neurotherapeutics 10:1, 77-86
CrossRef69
Mark S George, Gary Aston-Jones. (2010) Noninvasive techniques for probing neurocircuitry and treating illness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). Neuropsychopharmacology 35:1, 301-316
CrossRef70
T. Michael Kashner, Madhukar H. Trivedi, Annie Wicker, Maurizio Fava, Stephen R. Wisniewski, A. John Rush. (2009) The Impact of Nonclinical Factors on Care Use for Patients with Depression: A STAR*D Report. CNS Neuroscience & Therapeutics 15:4, 320-332
CrossRef71
Tracy L. Greer, Madhukar H. Trivedi. (2009) Exercise in the treatment of depression. Current Psychiatry Reports 11:6, 466-472
CrossRef72
Gahan J. Pandina, Dennis A. Revicki, Leah Kleinman, Ibrahim Turkoz, Jasmanda H. Wu, Mary J. Kujawa, Ramy Mahmoud, Georges M. Gharabawi. (2009) Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: A secondary analysis of a randomized, double-blind, placebo-controlled trial. Journal of Affective Disorders 118:1-3, 139-146
CrossRef73
Ian A. Cook, Aimee M. Hunter, Michelle Abrams, Barbara Siegman, Andrew F. Leuchter. (2009) Midline and right frontal brain function as a physiologic biomarker of remission in major depression. Psychiatry Research: Neuroimaging 174:2, 152-157
CrossRef74
Hans-Jürgen Möller. (2009) Is evidence sufficient for evidence-based medicine?. European Archives of Psychiatry and Clinical Neuroscience 259:S2, 167-172
CrossRef75
Barbara J. Messinger-Rapport, David R. Thomas, Julie K. Gammack, John E. Morley. (2009) Clinical Update on Nursing Home Medicine: 2009. Journal of the American Medical Directors Association 10:8, 530-553
CrossRef76
Raymond W. Lam, Sidney H. Kennedy, Sophie Grigoriadis, Roger S. McIntyre, Roumen Milev, Rajamannar Ramasubbu, Sagar V. Parikh, Scott B. Patten, Arun V. Ravindran. (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.. Journal of Affective Disorders 117, S26-S43
CrossRef77
Philip M. Becker, Muhammad Sattar. (2009) Treatment of sleep dysfunction and psychiatric disorders. Current Treatment Options in Neurology 11:5, 349-357
CrossRef78
Andrew F. Leuchter, Ian A. Cook, William S. Gilmer, Lauren B. Marangell, Karl S. Burgoyne, Robert H. Howland, Madhukar H. Trivedi, Sidney Zisook, Rakesh Jain, Maurizio Fava, Dan Iosifescu, Scott Greenwald. (2009) Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Research 169:2, 132-138
CrossRef79
Peter Giacobbe, Helen S. Mayberg, Andres M. Lozano. (2009) Treatment resistant depression as a failure of brain homeostatic mechanisms: Implications for deep brain stimulation. Experimental Neurology 219:1, 44-52
CrossRef80
Rachel M. Henke, Alan M. Zaslavsky, Thomas G. McGuire, John Z. Ayanian, Lisa V. Rubenstein. (2009) Clinical Inertia in Depression Treatment. Medical Care 47:9, 959-967
CrossRef81
Sheldon H. Preskorn. (2009) How and Why Study Designs Affect the Nature and Validity of Study Results: Appearance Versus True Knowledge. Part II. Journal of Psychiatric Practice 15:5, 402-407
CrossRef82
A. John Rush, Susan E. Siefert. (2009) Clinical issues in considering vagus nerve stimulation for treatment-resistant depression. Experimental Neurology 219:1, 36-43
CrossRef83
Sidney H. Kennedy. (2009) Agomelatine. CNS Drugs 23:Supplement 2, 41-47
CrossRef84
Roy H Perlis, Amanda Patrick, Jordan W Smoller, Philip S Wang. (2009) When is Pharmacogenetic Testing for Antidepressant Response Ready for the Clinic? A Cost-effectiveness Analysis Based on Data from the STAR*D Study. Neuropsychopharmacology 34:10, 2227-2236
CrossRef85
T. Michael Kashner, Madhukar H. Trivedi, Annie Wicker, Maurizio Fava, Kathy Shores-Wilson, Stephen R. Wisniewski, A. John Rush. (2009) Release bias in accessing medical records in clinical trials: a STAR*D report. International Journal of Methods in Psychiatric Research 18:3, 147-158
CrossRef86
Andreas B. Schmitt, Michael Bauer, Hans-Peter Volz, Hans-Jürgen Moeller, Qin Jiang, Philip T. Ninan, Peter-Andreas Loeschmann. (2009) Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity. European Archives of Psychiatry and Clinical Neuroscience 259:6, 329-339
CrossRef87
Michael E. Thase, Aaron M. Koenig. 2009. Outcomes in the Treatment of Major Depressive Disorder. , 22-53.
CrossRef88
Michael Bauer, Andrea Pfennig, Michael Linden, Michael N. Smolka, Peter Neu, Mazda Adli. (2009) Efficacy of an Algorithm-Guided Treatment Compared With Treatment as Usual. Journal of Clinical Psychopharmacology 29:4, 327-333
CrossRef89
Nhu Huynh, Roger S. McIntyre. 2009. Algorithms: STAR*D, Positives, Negatives, and Implications for Clinical Practice. , 117-126.
CrossRef90
John M. Zajecka, Corey Goldstein. 2009. Combining Medications to Achieve Remission. , 54-100.
CrossRef91
Pierre Blier, Gabriella Gobbi, Julie E. Turcotte, Claude de Montigny, Nathalie Boucher, Chantal Hébert, Guy Debonnel. (2009) Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation. European Neuropsychopharmacology 19:7, 457-465
CrossRef92
Sheldon H. Preskorn. (2009) How and Why Study Designs Affect the Nature and Validity of Study Results: Appearance Versus True Knowledge. Part I. Journal of Psychiatric Practice 15:4, 306-310
CrossRef93
Jeffrey J Rakofsky, Paul E Holtzheimer, Charles B Nemeroff. (2009) Emerging targets for antidepressant therapies. Current Opinion in Chemical Biology 13:3, 291-302
CrossRef94
John J. Boren, Allan M. Leventhal, H. Edmund Pigott. (2009) Just How Effective are Antidepressant Medications? Results of a Major New Study. Journal of Contemporary Psychotherapy 39:2, 93-100
CrossRef95
Roy H Perlis, Gonzalo Laje, Jordan W Smoller, Maurizio Fava, A John Rush, Francis J McMahon. (2009) Genetic and Clinical Predictors of Sexual Dysfunction in Citalopram-Treated Depressed Patients. Neuropsychopharmacology 34:7, 1819-1828
CrossRef96
Joshua Kantrowitz, Leslie Citrome, Daniel Javitt. (2009) GABAB Receptors, Schizophrenia and Sleep Dysfunction. CNS Drugs PAP,
CrossRef97
Roy H. Perlis, Bonnie Fijal, David H. Adams, Virginia K. Sutton, Madhukar H. Trivedi, John P. Houston. (2009) Variation in Catechol-O-Methyltransferase Is Associated with Duloxetine Response in a Clinical Trial for Major Depressive Disorder. Biological Psychiatry 65:9, 785-791
CrossRef98
Chad D. Rethorst, Bradley M. Wipfli, Daniel M. Landers. (2009) The Antidepressive Effects of Exercise. Sports Medicine 39:6, 491-511
CrossRef99
Sheldon H. Preskorn. (2009) Treatment Options for the Patient Who Does Not Respond Well to Initial Antidepressant Therapy. Journal of Psychiatric Practice 15:3, 202-210
CrossRef100
Jay D. Amsterdam, Justine Shults. (2009) Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?. Journal of Affective Disorders 115:1-2, 234-240
CrossRef101
Diane Warden, A. John Rush, Stephen R. Wisniewski, Ira M. Lesser, Susan G. Kornstein, G. K. Balasubramani, Michael E. Thase, Sheldon H. Preskorn, Andrew A. Nierenberg, Elizabeth A. Young, Kathy Shores-Wilson, Madhukar H. Trivedi. (2009) What predicts attrition in second step medication treatments for depression?: a STAR*D Report. The International Journal of Neuropsychopharmacology 12:04, 459
CrossRef102
Michael Bauer, Puvan Tharmanathan, Hans-Peter Volz, Hans-Juergen Moeller, Nick Freemantle. (2009) The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression. European Archives of Psychiatry and Clinical Neuroscience 259:3, 172-185
CrossRef103
Charles A. Henry, David Shervin, Ann Neumeyer, Ronald Steingard, Jessaca Spybrook, Roula Choueiri, Margaret Bauman. (2009) Retrial of Selective Serotonin Reuptake Inhibitors in Children with Pervasive Developmental Disorders: A Retrospective Chart Review. Journal of Child and Adolescent Psychopharmacology 19:2, 111-117
CrossRef104
Catherine Reed, Brigitta U. Monz, David G.S. Perahia, Paul Gandhi, Michael Bauer, Nicolas Dantchev, Koen Demyttenaere, Ana Garcia-Cebrian, Luigi Grassi, Deborah Quail, Andre Tylee, Angel L. Montejo. (2009) Quality of life outcomes among patients with depression after 6 months of starting treatment: Results from FINDER. Journal of Affective Disorders 113:3, 296-302
CrossRef105
Edward S. Friedman, Michael E. Thase, Stephen R. Wisniewski, Madhukar H. Trivedi, Melanie M. Biggs, Maurizio Fava, Diane Warden, George Niederehe, James F. Luther, A. John Rush. (2009) Cognitive Therapy Augmentation versus CT Switch Treatment: A STAR*D Report. International Journal of Cognitive Therapy 2:1, 66-87
CrossRef106
Henricus G Ruhé, Jan Booij, Henk C v Weert, Johannes B Reitsma, Eric J F Fransen, Martin C Michel, Aart H Schene. (2009) Evidence Why Paroxetine Dose Escalation is Not Effective in Major Depressive Disorder: A Randomized Controlled Trial With Assessment of Serotonin Transporter Occupancy. Neuropsychopharmacology 34:4, 999-1010
CrossRef107
Dominick Esposito, Peter Wahl, Gregory Daniel, Michael A. Stoto, M. Haim Erder, Thomas W. Croghan. (2009) Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States. Clinical Therapeutics 31:3, 644-656
CrossRef108
Sagar V Parikh. (2009) Antidepressants are not all created equal. The Lancet 373:9665, 700-701
CrossRef109
Andrew A. Nierenberg, Madhukar H. Trivedi, Bradley N. Gaynes, Jeff Mitchell, Lori L. Davis, Mustafa M. Husain, Stephen R. Wisniewski, Maurizio Fava, Diane Warden, James F. Luther, Adrienne O. van Nieuwenhuizen, David W. Morris, Richard C. Shelton, A. John Rush. (2009) Effectiveness study of venlafaxine-XR combined with aripiprazole for chronic or recurrent major depressive disorder. Australian and New Zealand Journal of Psychiatry 43:10, 956-967
CrossRef110
Robert H. Howland, A. John Rush, Stephen R. Wisniewski, Madhukar H. Trivedi, Diane Warden, Maurizio Fava, Lori L. Davis, G.K. Balasubramani, Patrick J. McGrath, Susan R. Berman. (2009) Concurrent anxiety and substance use disorders among outpatients with major depression: Clinical features and effect on treatment outcome. Drug and Alcohol Dependence 99:1-3, 248-260
CrossRef111
Cindy Claassen, Ben Kurian, Madhukar H. Trivedi, Bruce D. Grannemann, Ekta Tuli, Ronny Pipes, Anne Marie Preston, Ariell Flood. (2009) Telephone-based assessments to minimize missing data in longitudinal depression trials: A project IMPACTS study report. Contemporary Clinical Trials 30:1, 13-19
CrossRef112
George I. Papakostas, Rena Cooper-Kazaz, Bente C. Appelhof, Michael A. Posternak, Daniel P. Johnson, Anne Klibanski, Bernard Lerer, Maurizio Fava. (2009) Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. International Clinical Psychopharmacology 24:1, 19-25
CrossRef113
Mark Olfson, Steven Marcus, George Wan. (2009) Stimulant Dosing for Children With ADHD: A Medical Claims Analysis. Journal of the American Academy of Child & Adolescent Psychiatry 48:1, 51-59
CrossRef114
Sheldon H. Preskorn. (2009) Results of the STAR*D Study: Implications for Clinicians and Drug Developers. Journal of Psychiatric Practice 15:1, 45-49
CrossRef115
Dentzer, Susan. (2009) Communicating Medical News — Pitfalls of Health Care Journalism. New England Journal of Medicine 360:1, 1-3
Full Text116
Sanjay J. Mathew. (2008) Treatment-resistant depression: recent developments and future directions. Depression and Anxiety 25:12, 989-992
CrossRef117
Michael E. Thase. (2008) Prediction of outcome to a second trial of antidepressant medications following nonremission with citalopram therapy. Current Psychiatry Reports 10:6, 449-451
CrossRef118
George I. Papakostas, Richard C. Shelton. (2008) Use of atypical antipsychotics for treatment-resistant major depressive disorder. Current Psychiatry Reports 10:6, 481-486
CrossRef119
Sheldon H. Preskorn, Bryan Baker, Sheela Kolluri, Frank S. Menniti, Michael Krams, Jaren W. Landen. (2008) An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder. Journal of Clinical Psychopharmacology 28:6, 631-637
CrossRef120
Kenneth A. Kobak, Janet B.W. Williams, Elizabeth Jeglic, Donna Salvucci, Ian R. Sharp. (2008) Face-to-face versus remote administration of the Montgomery-Asberg Depression Rating Scale using videoconference and telephone. Depression and Anxiety 25:11, 913-919
CrossRef121
Anand K. Pandurangi, Alican Dalkilic. (2008) Polypharmacy With Second-Generation Antipsychotics: A Review of Evidence. Journal of Psychiatric Practice 14:6, 345-367
CrossRef122
Roy H Perlis, Priya Moorjani, Jesen Fagerness, Shaun Purcell, Madhukar H Trivedi, Maurizio Fava, A John Rush, Jordan W Smoller. (2008) Pharmacogenetic Analysis of Genes Implicated in Rodent Models of Antidepressant Response: Association of TREK1 and Treatment Resistance in the STAR*D Study. Neuropsychopharmacology 33:12, 2810-2819
CrossRef123
Robert H. Howland. (2008) Sequenced Treatment Alternatives to Relieve Depression (star*d). Journal of Psychosocial Nursing and Mental Health Services 46:10, 21-24
CrossRef124
&NA;. (2008) Desvenlafaxine for Depression. Obstetrics & Gynecology 112:3, 694-696
CrossRef125
Mark S. George, Harold A. Sackeim. (2008) Brain Stimulation, Revolutions, and the Shifting Time Domain of Depression. Biological Psychiatry 64:6, 447-448
CrossRef126
Robert H. Howland, Robert H. Howland. (2008) Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Journal of Psychosocial Nursing and Mental Health Services 46:9, 21-24
CrossRef127
Martin Bares, Martin Brunovsky, Miloslav Kopecek, Tomas Novak, Pavla Stopkova, Jiri Kozeny, Peter Sos, Vladimir Krajca, Cyril Höschl. (2008) Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. European Psychiatry 23:5, 350-355
CrossRef128
Marianne Gorlyn, John G. Keilp, Michael F. Grunebaum, Bonnie P. Taylor, Maria A. Oquendo, Gerard E. Bruder, Jonathan W. Stewart, Gil Zalsman, J. John Mann. (2008) Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. Journal of Neural Transmission 115:8, 1213-1219
CrossRef129
Mary E. Burman, Jennifer Petrie. (2008) Depression and anxiety outcomes at a free clinic in a rural state. Journal of the American Academy of Nurse Practitioners 20:7, 359-366
CrossRef130
John J. Barry, Alan B. Ettinger, Peggy Friel, Frank G. Gilliam, Cynthia L. Harden, Bruce Hermann, Andres M. Kanner, Rochelle Caplan, Sigita Plioplys, Jay Salpekar, David Dunn, Joan Austin, Jana Jones. (2008) Consensus statement: The evaluation and treatment of people with epilepsy and affective disorders. Epilepsy & Behavior 13, S1-S29
CrossRef131
Heather E. McNeely, Helen S. Mayberg, Andres M. Lozano, Sidney H. Kennedy. (2008) Neuropsychological Impact of Cg25 Deep Brain Stimulation for Treatment-Resistant Depression. The Journal of Nervous and Mental Disease 196:5, 405-410
CrossRef132
Michael E. Thase, Timothey Denko. (2008) Pharmacotherapy of Mood Disorders. Annual Review of Clinical Psychology 4:1, 53-91
CrossRef133
David W. Morris, Madhukar H. Trivedi, A. John Rush. (2008) Folate and Unipolar Depression. The Journal of Alternative and Complementary Medicine 14:3, 277-285
CrossRef134
George I. Papakostas, Maurizio Fava, Michael E. Thase. (2008) Treatment of SSRI-Resistant Depression: A Meta-Analysis Comparing Within- Versus Across-Class Switches. Biological Psychiatry 63:7, 699-704
CrossRef135
Steven D Targum, Mark H Pollack, Maurizio Fava. (2008) Redefining Affective Disorders: Relevance for Drug Development. CNS Drug Reviews 14:1, 2-9
CrossRef136
John P. O'Reardon, Karen E. Groff, Albert J. Stunkard, Kelly C. Allison. (2008) Night Eating Syndrome and Results from the First Placebo-Controlled Trial of Treatment, with the SSRI Medication, Sertraline: Implications for Clinical Practice. Progress in Neurotherapeutics and Neuropsychopharmacology 3:01,
CrossRef137
Steven D Targum, Mark H Pollack, Maurizio Fava. (2008) Redefining Affective Disorders: Relevance for Drug Development. CNS Neuroscience & Therapeutics 14:1, 2-9
CrossRef138
Mark D. Miller. (2008) Using interpersonal therapy (IPT) with older adults today and tomorrow: A review of the literature and new developments. Current Psychiatry Reports 10:1, 16-22
CrossRef139
Gin S. Malhi, Felicity Ng, Michael Berk. (2008) Dual–dual action? Combining venlafaxine and mirtazapine in the treatment of depression. Australian and New Zealand Journal of Psychiatry 42:4, 346-349
CrossRef140
George I. Papakostas, Madhukar H. Trivedi, Jonathan E. Alpert, Cheryl A. Seifert, Alok Krishen, Elizabeth P. Goodale, Vivian L. Tucker. (2008) Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: A meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. Journal of Psychiatric Research 42:2, 134-140
CrossRef141
Sohita Dhillon, Lily P H Yang, Monique P Curran. (2008) Bupropion. Drugs 68:5, 653-689
CrossRef142
Chanaka Wijeratne, Perminder Sachdev. (2008) Treatment-resistant depression: critique of current approaches. Australian and New Zealand Journal of Psychiatry 42:9, 751-762
CrossRef143
Michael Bauer, Brigitta U. Monz, Angel L. Montejo, Deborah Quail, Nicolas Dantchev, Koen Demyttenaere, Ana Garcia-Cebrian, Luigi Grassi, David G.S. Perahia, Catherine Reed, Andre Tylee. (2008) Prescribing patterns of antidepressants in Europe: Results from the Factors Influencing Depression Endpoints Research (FINDER) study. European Psychiatry 23:1, 66-73
CrossRef144
Michael Alan Taylor, Max Fink. (2008) Restoring melancholia in the classification of mood disorders. Journal of Affective Disorders 105:1-3, 1-14
CrossRef145
David V Sheehan, Matthew S Keene, Michael Eaddy, Stan Krulewicz, John E Kraus, David J Carpenter. (2008) Differences in Medication Adherence and Healthcare Resource Utilization Patterns. CNS Drugs 22:11, 963-973
CrossRef146
Rongrong Tao, Jarrette K Moore, Taryn L Mayes, Graham J Emslie. (2007) Depression in children and adolescents: optimizing treatment. Pediatric Health 1:2, 217-232
CrossRef147
Madhukar H Trivedi, A John Rush, Bradley N Gaynes, Jonathan W Stewart, Stephen R Wisniewski, Diane Warden, Louise Ritz, James F Luther, Diane Stegman, Joanne Deveaugh-Geiss, Robert Howland. (2007) Maximizing the Adequacy of Medication Treatment in Controlled Trials and Clinical Practice: STAR*D Measurement-Based Care. Neuropsychopharmacology 32:12, 2479-2489
CrossRef148
Mazda Adli, Dorothea L. Hollinde, Thomas Stamm, Katja Wiethoff, Martina Tsahuridu, Julia Kirchheiner, Andreas Heinz, Michael Bauer. (2007) Response to Lithium Augmentation in Depression is Associated with the Glycogen Synthase Kinase 3-Beta −50T/C Single Nucleotide Polymorphism. Biological Psychiatry 62:11, 1295-1302
CrossRef149
Ardesheer Talati, Priya J. Wickramaratne, Daniel J. Pilowsky, Jonathan E. Alpert, Gabriele Cerda, Judy Garber, Carroll W. Hughes, Cheryl A. King, Erin Malloy, A. Bela Sood, Helen Verdeli, Madhukar H. Trivedi, A. John Rush, Myrna M. Weissman. (2007) Remission of maternal depression and child symptoms among single mothers. Social Psychiatry and Psychiatric Epidemiology 42:12, 962-971
CrossRef150
John P. O’Reardon, H. Brent Solvason, Philip G. Janicak, Shirlene Sampson, Keith E. Isenberg, Ziad Nahas, William M. McDonald, David Avery, Paul B. Fitzgerald, Colleen Loo, Mark A. Demitrack, Mark S. George, Harold A. Sackeim. (2007) Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial. Biological Psychiatry 62:11, 1208-1216
CrossRef151
George I. Papakostas, Michael E. Thase, Maurizio Fava, J. Craig Nelson, Richard C. Shelton. (2007) Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents. Biological Psychiatry 62:11, 1217-1227
CrossRef152
Diane Warden, A. John Rush, Madhukar H. Trivedi, Maurizio Fava, Stephen R. Wisniewski. (2007) The STAR*D project results: A comprehensive review of findings. Current Psychiatry Reports 9:6, 449-459
CrossRef153
Max Fink. (2007) What We Learn About Continuation Treatments From the Collaborative Electroconvulsive Therapy Studies. The Journal of ECT 23:4, 215-218
CrossRef154
T. Michael Kashner, Steven S. Henley, Richard M. Golden, A. John Rush, Robin B. Jarrett. (2007) Assessing the preventive effects of cognitive therapy following relief of depression: A methodological innovation. Journal of Affective Disorders 104:1-3, 251-261
CrossRef155
Unützer, Jürgen, . (2007) Late-Life Depression. New England Journal of Medicine 357:22, 2269-2276
Full Text156
Ira M. Lesser, Daniel B. Castro, Bradley N. Gaynes, Jodi Gonzalez, A John Rush, Jonathan E. Alpert, Madhukar Trivedi, James F. Luther, Stephen R. Wisniewski. (2007) Ethnicity/Race and Outcome in the Treatment of Depression. Medical Care 45:11, 1043-1051
CrossRef157
(2007) Practice Parameter for the Assessment and Treatment of Children and Adolescents With Depressive Disorders. Journal of the American Academy of Child & Adolescent Psychiatry 46:11, 1503-1526
CrossRef158
Kurt Kroenke, Matthew Bair, Teresa Damush, Shawn Hoke, Gloria Nicholas, Carol Kempf, Monica Huffman, Jingwei Wu, Jason Sutherland. (2007) Stepped Care for Affective Disorders and Musculoskeletal Pain (SCAMP) study. General Hospital Psychiatry 29:6, 506-517
CrossRef159
Doron Mazeh, Baruch Shahal, Alex Aviv, Hanna Zemishlani, Yoram Barak. (2007) A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. International Clinical Psychopharmacology 22:6, 371-375
CrossRef160
Jeanne Leventhal Alexander, Gregg Richardson, Lydia Grypma, Enid M Hunkeler. (2007) Collaborative depression care, screening, diagnosis and specificity of depression treatments in the primary care setting. Expert Review of Neurotherapeutics 7:11s, S59-S80
CrossRef161
Thomas J. Craig, Steven Grossman, Evelyn J. Bromet, Laura J. Fochtmann, Gabrielle A. Carlson. (2007) Medication use patterns and two-year outcome in first-admission patients with major depressive disorder with psychotic features. Comprehensive Psychiatry 48:6, 497-503
CrossRef162
Jared R. Tinklenberg, Helena C. Kraemer, Kristine Yaffe, Leslie Ross, Javaid Sheikh, John W. Ashford, Jerome A. Yesavage, Joy L. Taylor. (2007) Donepezil Treatment and Alzheimer Disease: Can the Results of Randomized Clinical Trials Be Applied to Alzheimer Disease Patients in Clinical Practice?. American Journal of Geriatric Psychiatry 15:11, 953-960
CrossRef163
Jean Pierre Olié, Siegfried Kasper. (2007) Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. The International Journal of Neuropsychopharmacology 10:05,
CrossRef164
Raymond W. Lam. (2007) High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder. International Clinical Psychopharmacology 22:Supplement 2, S21-S25
CrossRef165
Gerard E. Bruder, Jonathan W. Stewart, Jennifer D. Schaller, Patrick J. McGrath. (2007) Predicting therapeutic response to secondary treatment with bupropion: Dichotic listening tests of functional brain asymmetry. Psychiatry Research 153:2, 137-143
CrossRef166
James R. McKay. (2007) Lessons Learned From Psychotherapy Research. Alcoholism: Clinical and Experimental Research 31:s3, 48s-54s
CrossRef167
Robert A. Cain. (2007) Navigating the Sequenced Treatment Alternatives to Relieve Depression (STAR
D) Study: Practical Outcomes and Implications for Depression Treatment in Primary Care. Primary Care: Clinics in Office Practice 34:3, 505-519
CrossRef168
H.-J. Möller, W. Maier. (2007) Probleme der „evidence-based medicine“ in der Psychopharmakotherapie: Problematik der Evidenzgraduierung und der Evidenzbasierung komplexer klinischer Entscheidungsprozesse. Der Nervenarzt 78:9, 1014-1027
CrossRef169
BUSHRA NAZ, THOMAS J. CRAIG, EVELYN J. BROMET, STEPHEN J. FINCH, LAURA J. FOCHTMANN, GABRIELLE A. CARLSON. (2007) Remission and relapse after the first hospital admission in psychotic depression: a 4-year naturalistic follow-up. Psychological Medicine 37:08, 1173
CrossRef170
George I. Papakostas, Susan G. Kornstein, Anita H. Clayton, Claudio N. Soares, Lindsay A. Hallett, Alok Krishen, Vivian L. Tucker. (2007) Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender???age interactions. International Clinical Psychopharmacology 22:4, 226-229
CrossRef171
Deborah Antai-Otong. (2007) The Art of Prescribing.. Perspectives In Psychiatric Care 43:3, 142-145
CrossRef172
Menelas N. Pangalos, Lee E. Schechter, Orest Hurko. (2007) Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nature Reviews Drug Discovery 6:7, 521-532
CrossRef173
Teresa A. Pigott, Apurva Prakash, Lesley M. Arnold, Scott T. Aaronson, Craig H. Mallinckrodt, Madelaine M. Wohlreich. (2007) Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder*. Current Medical Research and Opinion 23:6, 1303-1318
CrossRef174
Kathleen M. Carroll, Bruce J. Rounsaville. (2007) A vision of the next generation of behavioral therapies research in the addictions. Addiction 102:6, 850-862
CrossRef175
CARROLL W. HUGHES, GRAHAM J. EMSLIE, M. LYNN CRISMON, KELLY POSNER, BORIS BIRMAHER, NEAL RYAN, PETER JENSEN, JOHN CURRY, BENEDETTO VITIELLO, MOLLY LOPEZ, STEVE P. SHON, STEVEN R. PLISZKA, MADHUKAR H. TRIVEDI. (2007) Texas Children's Medication Algorithm Project: Update From Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. Journal of the American Academy of Child & Adolescent Psychiatry 46:6, 667-686
CrossRef176
James N. Kimball. (2007) Electroconvulsive Therapy—An Outdated Treatment, or One Whose Time Has Come?. Southern Medical Journal 100:5, 462-463
CrossRef177
Madhukar H. Trivedi, Ella J. Daly. (2007) Measurement-based care for refractory depression: A clinical decision support model for clinical research and practice. Drug and Alcohol Dependence 88, S61-S71
CrossRef178
Charles B. Nemeroff. (2007) The burden of severe depression: A review of diagnostic challenges and treatment alternatives. Journal of Psychiatric Research 41:3-4, 189-206
CrossRef179
Harold W. Goforth, Brendan T. Carroll. (2007) Aripiprazole Augmentation of Tranylcypromine in Treatment-Resistant Major Depression. Journal of Clinical Psychopharmacology 27:2, 216-217
CrossRef180
Andrew A. Nierenberg, Judith Katz, Maurizio Fava. (2007) A Critical Overview of the Pharmacologic Management of Treatment-Resistant Depression. Psychiatric Clinics of North America 30:1, 13-29
CrossRef181
Anita H Clayton. (2007) Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?. Expert Opinion on Pharmacotherapy 8:4, 457-466
CrossRef182
Khrista Boylan, Soledad Romero, Boris Birmaher. (2007) Psychopharmacologic treatment of pediatric major depressive disorder. Psychopharmacology 191:1, 27-38
CrossRef183
Barondes, Samuel H., . (2007) Book Review. New England Journal of Medicine 356:6, 646-647
Full Text184
Andrew A. Nierenberg, John H. Greist, Craig H. Mallinckrodt, Apurva Prakash, Angelo Sambunaris, Gary D. Tollefson, Madelaine M. Wohlreich. (2007) Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study*. Current Medical Research and Opinion 23:2, 401-416
CrossRef185
M. Fink, M. A. Taylor. (2007) Resurrecting melancholia. Acta Psychiatrica Scandinavica 115:s433, 14-20
CrossRef186
Chi-Un Pae, Ashwin A Patkar. (2007) Paroxetine: current status in psychiatry. Expert Review of Neurotherapeutics 7:2, 107-120
CrossRef187
Dominic Hodgkin, Constance M. Horgan, Deborah W. Garnick, Elizabeth Len Merrick, Joanna Volpe-Vartanian. (2007) Management of access to branded psychotropic medications in private health plans. Clinical Therapeutics 29:2, 371-380
CrossRef188
(2007) Melancholia: Beyond DSM, Beyond Neurotransmitters, May 2?4, 2006, Copenhagen Marriott.. Acta Psychiatrica Scandinavica 115:s433, 136-183
CrossRef189
Mary Jo Larson, Kay Miller, Kathleen J. Fleming. (2007) Treatment with Antidepressant Medications in Private Health Plans. Administration and Policy in Mental Health and Mental Health Services Research 34:2, 116-126
CrossRef190
William G Honer, Allen E Thornton, Megan Sherwood, G ??William MacEwan, Tom S Ehmann, Richard Williams, Lili C Kopala, Ric Procyshyn, Alasdair M Barr. (2007) Conceptual and Methodological Issues??in the Design of Clinical Trials??of Antipsychotics for the Treatment??of Schizophrenia. CNS Drugs 21:9, 699-714
CrossRef191
Nadja Maric, Sandra Pekic, Mira Doknic, Miroslava Jasovic-Gasic, Vlada Zivkovic, Marko Stojanovic, Branko Djurovic, Vera Popovic. (2007) Depression following Traumatic Brain Injury Associated with Isolated Growth Hormone Deficiency: Two Case Reports. Hormone Research 67:1, 177-179
CrossRef192
Mark S George, Ziad Nahas, Jeffrey J Borckardt, Berry Anderson, Carol Burns, Samet Kose, E Baron Short. (2007) Vagus nerve stimulation for the treatment of depression and other neuropsychiatric disorders. Expert Review of Neurotherapeutics 7:1, 63-74
CrossRef193
Paul E Holtzheimer, Charles B Nemeroff. (2006) Emerging treatments for depression. Expert Opinion on Pharmacotherapy 7:17, 2323-2339
CrossRef194
Peter Giacobbe, Sidney H. Kennedy. (2006) Deep brain stimulation for treatment-resistant depression: A psychiatric perspective. Current Psychiatry Reports 8:6, 437-444
CrossRef195
James R. McKay. (2006) Continuing care in the treatment of addictive disorders. Current Psychiatry Reports 8:5, 355-362
CrossRef196
Philip M. Becker. (2006) Treatment of sleep dysfunction and psychiatric disorders. Current Treatment Options in Neurology 8:5, 367-375
CrossRef197
David Shannahoff-Khalsa. (2006) A Perspective on the Emergence of Meditation Techniques for Medical Disorders. The Journal of Alternative and Complementary Medicine 12:8, 709-713
CrossRef198
Kevin F Foley, Kevin P DeSanty, Richard E Kast. (2006) Bupropion: pharmacology and therapeutic applications. Expert Review of Neurotherapeutics 6:9, 1249-1265
CrossRef199
Sheila A Doggrell. (2006) After the failure of citalopram for depression, what next?. Expert Opinion on Pharmacotherapy 7:11, 1515-1518
CrossRef200
J. M. A. Sitsen. (2006) Een serotonineheropnameremmer werkt niet voldoende bij depressie. En nu?. Medisch-Farmaceutische Mededelingen 44:7, 201-202
CrossRef201
. (2006) Een depressie die niet geneest met een SSRI. Wat nu?. Huisarts en Wetenschap 49:7, 489-489
CrossRef202
(2006) Depression — Augmentation or Switch after Initial SSRI Treatment. New England Journal of Medicine 354:24, 2611-2613
Full Text203
Mazda Adli, Michael Bauer, A. John Rush. (2006) Algorithms and Collaborative-care Systems for Depression: Are They Effective and Why?. Biological Psychiatry 59:11, 1029-1038
CrossRef204
Trivedi, Madhukar H., Fava, Maurizio, Wisniewski, Stephen R., Thase, Michael E., Quitkin, Frederick, Warden, Diane, Ritz, Louise, Nierenberg, Andrew A., Lebowitz, Barry D., Biggs, Melanie M., Luther, James F., Shores-Wilson, Kathy, Rush, A. John, . (2006) Medication Augmentation after the Failure of SSRIs for Depression. New England Journal of Medicine 354:12, 1243-1252
Full Text205
Rubinow, David R., . (2006) Treatment Strategies after SSRI Failure — Good News and Bad News. New England Journal of Medicine 354:12, 1305-1307
Full Text
- Letters
